Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 759-765

  Thompson, Catherine I ^a,b   Barclay, Wendy S ^a   Zambon, Maria C ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

Haemagglutinin; Neuraminidase; Reverse genetics; Sialic acid; Zanamivir

Indexed keywords

HEMAGGLUTININ; ISOLEUCINE; LEUCINE; SIALIC ACID; SIALIDASE; SIALIDASE INHIBITOR; VALINE; ZANAMIVIR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; BINDING SITE; CELL STRAIN; CHICKEN; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ASSAY; ENZYME INHIBITION; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; GUINEA PIG; HEMAGGLUTINATION TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN MOTIF; RECEPTOR BINDING; SPECIES DIFFERENCE; TURKEY (BIRD); VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS ISOLATION; VIRUS RECOMBINANT;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHICKENS; CLONING, MOLECULAR; DISEASE PROGRESSION; ENZYME INHIBITORS; GREAT BRITAIN; GUANIDINES; HEMAGGLUTINATION TESTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; PLAQUE ASSAY; PLASMIDS; PYRANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALIC ACIDS; SPECIES SPECIFICITY; TURKEYS; ZANAMIVIR;

EID: 2442667775     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh155     Document Type: Article

References (39)

1. Gubareva, L. V., Matrosovich, M. N., Brenner, M. K. et al. (1998). Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Journal of Infectious Diseases 178, 1257-62.
2. Tisdale, M. (2000). Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Reviews in Medical Virology 10, 45-55.
3. Rogers, G. N. & Paulson, J. C. (1983). Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127, 361-73.
4. Connor, R. J., Kawaoka, Y., Webster, R. G. et al. (1994). Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205, 17-23.
5. Couceiro, J. N. S. S., Paulson, J. C. & Baum, L. G. (1993). Influenza virus strains selectively recognise sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Research 29, 155-65.
6. Baum, L. G. & Paulson, J. C. (1990). Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochemica 40, Suppl., 35-8.
7. Weis, W., Brown, J. H., Cusack, S. et al. (1988). Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333, 426-31.
8. Baum, L. G. & Paulson, J. C. (1991). The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology 180, 10-5.
9. Kaverin, N. V., Gambaryan, A. S., Bovin, N. V. et al. (1998). Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. Virology 244, 315-21.
10. Matrosovich, M., Zhou, N., Kawaoka, Y. et al. (1999). The surface glycoproteins of H5 influenza viruses isolated from humans, chickens and wild aquatic birds have distinguishable properties. Journal of Virology 73, 1146-55.
11. Wagner, R., Wolff, T., Herwig, A. et al. (2000). Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. Journal of Virology 74, 6316-23.
12. Ito, T., Suzuki, Y., Mitnaul, L. et al. (1997). Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology 227, 493-9.
13. Morishita, T., Kobayashi, S., Miyake, T. et al. (1993). Host-specific hemagglutination of influenza A (H1N1) virus. Microbiology and Immunology 37, 661-5.
14. Nobusawa, E., Ishihara, H., Morishita, T. et al. (2000). Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 278, 587-96.
15. Medeiros, R., Escriou, N., Naffakh, N. et al. (2001). Hemagglutinin residues of recent human A (H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology 289, 74-85.
16. Abed, Y., Bourgault, A.-M., Fenton, R. J. et al. (2002). Characterization of 2 influenza A (H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. Journal of Infectious Diseases 186, 1074-80.
17. McKimm-Breschkin, J. L., Blick, T. J., Sahasrabudhe, A. et al. (1996). Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrobial Agents and Chemotherapy 40, 40-6.
18. Potier, M., Mameli, L., Belisle, M. et al. (1979). Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Analytical Biochemistry 94, 287-96.
19. McKimm-Breschkin, J., Trivedi, T., Hampson, A. et al. (2003). Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial Agents and Chemotherapy 47, 2264-72.
20. Boom, R., Sol, C. J. A., Salimans, M. M. M. et al. (1990). Rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 28, 495-503.
21. Ellis, J. S., Fleming, D. M. & Zambon, M. C. (1997). Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. Journal of Clinical Microbiology 35, 2076-82.
22. Ellis, J. S., Chakraverty, P. & Clewley, J. P. (1995). Genetic and antigenic variation in the haemagglutinin of recently circulating human influenza A (H3N2) viruses in the United Kingdom. Archives of Virology 140, 1889-1904.
23. Neumann, G. & Kawaoka, Y. (1999). Genetic engineering of influenza and other negative-strand RNA viruses containing segmented genomes. Advances in Virus Research 53, 265-300.
24. Elleman, C. & Barclay, W. S. (2004). The influenza A virus matrix protein controls virus morphology. Virology in press.
25. Katz, J. M., Wang, M. & Webster, R. G. (1990). Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. Journal of Virology 64, 1808-11.
26. Woods, J. M., Bethell, R. C., Coates, J. A. V. et al. (1993). 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrobial Agents and Chemotherapy 37, 1473-9.
27. Gubareva, L. V., Webster, R. G. & Hayden, F. G. (2001). Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase in hibitor-resistant variants. Antimicrobial Agents and Chemotherapy 45, 3403-8.
28. Macken, C., Lu, H., Goodman, J. et al. (2001). The value of a data-base in surveillance and vaccine selection. In Options for the Control of Influenza IV (Osterhaus, A. D, M. E., Cox, N. & Hampson, A. W., Eds), pp. 103-6. Elsevier Science, Amsterdam.
29. Bush, R. M., Bender, C. A., Subbarao, K. et al. (1999). Predicting the evolution of human influenza A. Science 286, 1921-5.
30. Zambon, M. & Hayden, F. G. (2001). Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Research 49, 147-56.
31. Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J. et al. (1997). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New England Journal of Medicine 337, 874-80.
32. Baigent, S. J., Bethell, R. C. & McCauley, J. W. (1999). Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro. Virology 263, 323-38.
33. Ellis, J. S., Sadler, C. J., Laidler, P. et al. (1997). Analysis of influenza A H3N2 strains isolated in England during 1995-1996 using polymerase chain reaction restriction. Journal of Medical Virology 51, 234-41.
34. Mochalova, L., Gambaryan, A., Romanova, J. et al. (2003). Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology 313, 473-80.
35. Matrosovich, M., Tuzikov, A., Bovin, N. et al. (2000). Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. Journal of Virology 74, 8502-12.
36. Bethell, R. C., Hart, G. J., Blick, T. J. et al. (1999). Biochemical methods for the characterization of influenza viruses with reduced sensitivity to 4-Guanidino-Neu5Ac2en. In Antiviral Methods and Protocols (Kinchington, D. & Schinazi, R. F., Eds), pp. 367-73. Humana Press Inc., Totowa, NJ, USA.
37. Gerentes, L., Kessler, N. & Aymard, M. (1998). A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein. Journal of Virological Methods 73, 185-95.
38. Matrosovich, M., Matrosovich, T., Carr, J. et al. (2003). Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. Journal of Virology 77, 8418-25.
39. Gubareva, L. V., Kaiser, L., Matrosovich, M. N. et al. (2001). Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. Journal of Infectious Diseases 183, 523-31.